AZ planning benralizumab submissions for asthma

AstraZeneca plc (LSE:AZN; NYSE:AZN) said benralizumab ( MEDI-563) met the primary endpoint of significantly reducing annual asthma exacerbation rates

Read the full 192 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE